Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oosterkamp

Showing results (121-130 of 127) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 127 results.
Plos One|July 5, 2013
Genome analysis and physiological comparison of Alicycliphilus denitrificans strains BC and K601(T.)Margreet J Oosterkamp, Teun Veuskens, Flávia Talarico Saia, et al.
Cancer|March 3, 2023
Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinomaCynthia S E Hendrikse, Phyllis van der Ploeg, Nienke M A van de Kruis, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2025
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trialNoor Wortelboer, Seamus Kent, Inge R Konings, et al.
The Lancet. Oncology|July 19, 2014
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trialWalter Taal, Hendrika M Oosterkamp, Annemiek M E Walenkamp, et al.
Cancers|October 28, 2023
<sup>89</sup>Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility StudyD G J Linders, M M Deken, M A van Dam, et al.
Iscience|August 29, 2024
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trialMark Opdam, Annelot G J van Rossum, Marlous Hoogstraat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell MicroenvironmentsLennart Kester, Danielle Seinstra, Annelot G J van Rossum, et al.
Pageof 13

Showing results (121-130 of 127) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 127 results.
Plos One|July 5, 2013
Genome analysis and physiological comparison of Alicycliphilus denitrificans strains BC and K601(T.)Margreet J Oosterkamp, Teun Veuskens, Flávia Talarico Saia, et al.
Cancer|March 3, 2023
Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinomaCynthia S E Hendrikse, Phyllis van der Ploeg, Nienke M A van de Kruis, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2025
Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trialNoor Wortelboer, Seamus Kent, Inge R Konings, et al.
The Lancet. Oncology|July 19, 2014
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trialWalter Taal, Hendrika M Oosterkamp, Annemiek M E Walenkamp, et al.
Cancers|October 28, 2023
<sup>89</sup>Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility StudyD G J Linders, M M Deken, M A van Dam, et al.
Iscience|August 29, 2024
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trialMark Opdam, Annelot G J van Rossum, Marlous Hoogstraat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell MicroenvironmentsLennart Kester, Danielle Seinstra, Annelot G J van Rossum, et al.
Pageof 13